PRIP Scheme’s
Expression of Interest (EOI)
The Department of Pharmaceuticals announces the launch of the Expression of Interest (EoI) under the Scheme for Promotion of Research & Innovation in Pharma, MedTech Sector (PRIP)
The EoI has been designed to provide you with an opportunity to co-shape India’s journey towards becoming an R&D innovation hub. All interested entities are encouraged to participate in PRIP Scheme’s Expression of Interest (EoI) process and share description of suitable projects.
Please visit the scheme’s website to access the EoI form: https://pharma-dept.gov.in/prip/
About the PRIP Scheme:
The PRIP Scheme aims to transform India into a global powerhouse for R&D in the Pharma MedTech sector. The scheme has a total outlay of ₹5,000 Cr, of which ₹4,250 Cr is focused on accelerating investments in industry-led R&D projects within six priority research areas, including: New Chemical Entities, New Biological Entities and Phyto-pharmaceuticals, Complex generics and Biosimilars, Precision Medicine, Medical Devices, Orphan Drugs and Drug Development for Antimicrobial Resistance (AMR)
For any queries about the scheme or EoI process please write to us at support-prip@pharma-dept.gov.in
Scheme Overview
The Scheme for “Promotion of Research and Innovation in Pharma MedTech sector (PRIP)” has been launched by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, with the goal of transforming India into a global powerhouse for R&D in the Pharma MedTech sector. The scheme has been notified vide Gazette Notification No. 199 dated 17th August 2023. The scheme has a total financial outlay of Rs. 5,000 Crores, of which Rs 4,250 Crores is focused on accelerating investments in the R&D ecosystem within the sector.
The scheme proposes funding across 6 priority areas and 3 funding categories:
Priority Areas
There are six priority research areas which will be covered by the PRIP scheme
- New Chemical Entity, New Biological Entity and Phyto-pharmaceuticals
- Complex generics and Biosimilars
- Precision medicine (Targeted innovative therapeutics)
- Medical devices
- Orphan Drugs
- Drug development for AMR
Key Funding Categories
R&D projects (focused on one or more of the priority areas above) need to be submitted within one of the following three funding categories:
1. B I: Funding up to 35% of total project cost or ₹125 Cr (whichever is less)
- Applicants must be Pharmaceutical or MedTech companies with:
o Annual revenue ≥ Rs. 1,000 Cr (Pharma) or ≥ Rs. 250 Cr (MedTech)
o R&D expenditure of 3-5% (Pharma) or 1-3% (MedTech) of total revenue in the last five years
o Collaboration with a Government Research Institution (See Appendix II for more details)
o Projects in priority areas at any TRL 1 to 9
2. B II: Funding up to 35% of total project cost or Rs. 100 Cr (whichever is less)
- Entities working on R&D projects in priority areas that are at TRL 5 or 6
3. B III: Funding up to Rs. 1 Cr per project
- Startups and MSMEs working in priority areas at TRL 1 onwards to TRL 4
For more information on TRL, kindly refer to the Appendix III of the EoI document
Invitation for Expression of Interest - Department of Pharmaceuticals invites Expression of Interest (EoI) from interested entities – e.g.,
- Proprietary Firm or Partnership Firm or Limited Liability Partnership (LLP), Startups or a Company /Group
- of companies registered in India for project funding under the PRIP scheme.
- This EoI has been designed to provide you with an opportunity to co-shape India’s journey towards
- becoming an R&D innovation hub, by soliciting your inputs on:
- Current R&D projects in the scheme’s priority areas for PRIP funding consideration
- Challenges in execution of an R&D projects
- Actions to strengthen the R&D ecosystem for Pharma and MedTech innovation in India
Source: https://pharma-dept.gov.in/prip/